Plain-English translation of NCT04591483 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This is a natural history study, which means researchers are carefully tracking how a rare inherited eye disease called Stargardt-like macular dystrophy (STDG3) changes over time. Rather than testing a new drug, this study documents the disease's natural progression in patients who have specific genetic mutations. Understanding how the disease develops will help researchers design better treatments in the future.
Doctors have proposed new treatments for this condition, but they don't have enough long-term data on how the disease typically progresses in patients. By carefully tracking vision changes over several years, this study will give researchers the information they need to develop and test new therapies more effectively.
You likely qualify if…
You likely don't qualify if…
You will visit the National Eye Institute at the NIH Clinical Center in Bethesda, Maryland for eye exams and imaging tests over three years. During these visits, you'll have detailed eye scans (optical coherence tomography and autofluorescence imaging), vision tests, and sensitivity testing to measure how your eyesight is changing. The study tracks structural changes in your retina and how your vision is functioning over time, helping doctors understand the disease's natural progression.
AI-generated summary from trial data · Sep 18, 2026 · Not medical advice
United States